ACLX-001, a novel BCMA-targeted CAR-T cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner.

被引：0

|

作者：

Edwards, Justin P. ^{[1
]}

Buonato, Janine ^{[1
]}

LaFleur, David ^{[1
]}

Swers, Jeffrey ^{[1
]}

Mu, Jenny ^{[1
]}

Zaritskaya, Liubov ^{[1
]}

Ng, Sinnie ^{[1
]}

Gupta, Ankit ^{[1
]}

Wang, Hui ^{[1
]}

McCullough, Samantha ^{[1
]}

Hilbert, David ^{[1
]}

Tice, David ^{[1
]}

机构：

[1] Arcellx, Gaithersburg, MD USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1549

引用

收藏

页数：1

相关论文

共 3 条

[1] Novel CAR-T Cell Therapy that Can be Activated, Silenced, and Reprogrammed In Vivo with Soluble Protein Adapters in a Dose Dependent Manner
Buonato, Janine
Edwards, Justin
LaFleur, David
Swers, Jeff
Mu, Jenny
Zaritskaya, Liubov
Gupta, Ankit
Wang, Hui
Ng, Sinnie
Richman, Laura
Shen, Angela
Hilbert, David
MOLECULAR THERAPY, 2020, 28 (04) : 346 - 346
[2] ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner
Edwards, Justin P.
Zaritskaya, Liubov
Swers, Jeff
Ng, Sinnie
Mu, Jenny
Witter, Alexandra
Cheung, Laurene
McCullough, Samantha
LaFleur, David
Hilbert, David
Tice, David
CANCER RESEARCH, 2022, 82 (12)
[3] Design and Demonstration of Potent In Vitro and In Vivo Activity for CART-ddBCMA, a BCMA-Targeted CAR-T Cell Therapy Incorporating a Non-scFv Binding Domain
Buonato, Janine M.
Edwards, Justin
Zaritskaya, Liubov
Gupta, Ankit
Richman, Laura
Hilbert, David
LaFleur, David
Tice, David
MOLECULAR THERAPY, 2021, 29 (04) : 58 - 58